OnKure Therapeutics, Inc. SEC filings OKUR
OnKure Therapeutics, Inc. has 404 filings in SEC EDGAR's recent list, going back to Jan 8, 2018. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 4, 2026 | — |
| CORRESP | Letter to the SEC | Apr 30, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2026 | — |
| EFFECT | Filing | Nov 18, 2025 | — |
| EFFECT | Filing | Mar 21, 2025 | — |
| EFFECT | Filing | Oct 30, 2024 | — |
| CORRESP | Letter to the SEC | Oct 28, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2024 | — |
| D | Filing | Oct 21, 2024 | — |
| 425 | Filing | Oct 2, 2024 | — |
| 425 | Filing | Sep 20, 2024 | — |
| EFFECT | Filing | Aug 26, 2024 | — |
| CORRESP | Letter to the SEC | Aug 23, 2024 | — |
| CORRESP | Letter to the SEC | Aug 19, 2024 | — |
| 425 | Filing | Aug 13, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 26, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2024 | — |
| 425 | Filing | May 13, 2024 | — |
| EFFECT | Filing | Nov 21, 2023 | — |
| CORRESP | Letter to the SEC | Nov 17, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2023 | — |
| EFFECT | Filing | Jun 13, 2023 | — |
| CORRESP | Letter to the SEC | Jun 9, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 8, 2023 | — |
| EFFECT | Filing | May 9, 2022 | — |
| CORRESP | Letter to the SEC | May 5, 2022 | — |
| UPLOAD | Letter from the SEC | May 4, 2022 | — |
| SEC STAFF LETTER | Filing | Apr 8, 2021 | — |
| EFFECT | Filing | Apr 8, 2021 | — |
| CERT | Filing | Apr 8, 2021 | — |
| 8-A12B | Filing | Apr 6, 2021 | — |
| CORRESP | Letter to the SEC | Apr 6, 2021 | — |
| CORRESP | Letter to the SEC | Apr 6, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 22, 2021 | — |
| CORRESP | Letter to the SEC | Mar 19, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2021 | — |
| DRS | Filing | Feb 12, 2021 | — |
| D | Filing | Dec 21, 2020 | — |
| D | Filing | May 14, 2019 | — |
| D | Filing | Jan 8, 2018 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OKUR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1637715
- Former names
- Reneo Pharmaceuticals, Inc. (until Oct 2, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.